VUB

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Monday, September 25, 2023
Health, General Health, Research, Science, Optical, Biotechnology, University of Antwerp, Thalassemia, University, Doctor of Philosophy, HIV, Free University of Brussels (1834–1969), Medicine, Biogen, Beth Israel Deaconess Medical Center, CMO, Teaching hospital, Harvard Medical School, Graves' ophthalmopathy, VUB, Patient, Progressive multifocal leukoencephalopathy, Sickle cell disease, R, Therapy, Free University, Safety, TED, Pharmaceutical industry, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.
  • During her time at Agios, she has overseen early- and late-stage clinical development globally across multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
  • “I’ve dedicated much of my career to developing medicines for underserved patient populations across a range of therapeutic areas.
  • She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

Belgium Unveils its New International Branding Campaign Highlighting its Openness for Innovation

Retrieved on: 
Wednesday, May 24, 2023
Vaccine, DNA, Partnership, Reuters, United Nations, Racial discrimination, Perception, University, Cancer, Marriage, ULB, IMEC, KOF Globalisation Index, Research, COVID, Language, International trade, Movement, Wind, Virtue, Kool-Aid, 2021 Slovenian Presidency of the Council of the European Union, Alzheimer's disease, VUB, Climate change, AIDS, FPS, Non-governmental organization, Laboratory, United, Elimination, Council, European, Council Implementing Regulation (EU) No. 282/2011, Ghent University, Brussels Airport, Private law, International Convention on the Elimination of All Forms of Racial Discrimination, International Convention Concerning the Use of Broadcasting in the Cause of Peace, Minister for Foreign Trade and Development Cooperation (Netherlands), KU Leuven, Renewable energy, Tourism

BRUSSELS, May 24, 2023 /PRNewswire/ -- Today, Belgium unveiled its new international branding campaign titled " Embracing Openness ".

Key Points: 
  • BRUSSELS, May 24, 2023 /PRNewswire/ -- Today, Belgium unveiled its new international branding campaign titled " Embracing Openness ".
  • These survey findings have served as the basis for Belgium's new country branding strategy, along with an accompanying campaign that emphasizes Belgium's commitment to innovation, partnership, and diversity, encapsulated in the theme "Embracing openness".
  • The "Embracing Openness" campaign's goal is to contribute positively to the reputation of Belgium on the international stage.
  • In the coming years, additional campaign moments will align with trade missions, international conferences, and stakeholder events.

Belgium Unveils its New International Branding Campaign Highlighting its Openness for Innovation

Retrieved on: 
Wednesday, May 24, 2023
Vaccine, DNA, Partnership, Reuters, United Nations, Racial discrimination, Perception, University, Cancer, Marriage, ULB, IMEC, KOF Globalisation Index, Research, COVID, Language, International trade, Movement, Wind, Virtue, Kool-Aid, 2021 Slovenian Presidency of the Council of the European Union, Alzheimer's disease, VUB, Climate change, AIDS, FPS, Non-governmental organization, Laboratory, United, Elimination, Council, European, Council Implementing Regulation (EU) No. 282/2011, Ghent University, Brussels Airport, Private law, International Convention on the Elimination of All Forms of Racial Discrimination, International Convention Concerning the Use of Broadcasting in the Cause of Peace, Minister for Foreign Trade and Development Cooperation (Netherlands), KU Leuven, Renewable energy, Tourism

BRUSSELS, May 24, 2023 /PRNewswire/ -- Today, Belgium unveiled its new international branding campaign titled " Embracing Openness ".

Key Points: 
  • BRUSSELS, May 24, 2023 /PRNewswire/ -- Today, Belgium unveiled its new international branding campaign titled " Embracing Openness ".
  • These survey findings have served as the basis for Belgium's new country branding strategy, along with an accompanying campaign that emphasizes Belgium's commitment to innovation, partnership, and diversity, encapsulated in the theme "Embracing openness".
  • The "Embracing Openness" campaign's goal is to contribute positively to the reputation of Belgium on the international stage.
  • In the coming years, additional campaign moments will align with trade missions, international conferences, and stakeholder events.

VoxelSensors Raises €5M in Seed Funding for blending the physical and digital worlds through 3D perception

Retrieved on: 
Wednesday, May 17, 2023
Lighting, Education, Health, AWE, Extended reality, Perception, Reality, Augmented World Expo, VUB, Traction, Vrije Universiteit Amsterdam, Growth, Robotics, Investment, Augment, Software, Video game, Content-based image retrieval

VoxelSensors’ Switching Pixels® Active Event Sensor (SPAES) is a novel category of ultra-low power and ultra-low latency 3D perception sensors for Extended Reality (XR)1 to blend the physical and digital worlds.

Key Points: 
  • VoxelSensors’ Switching Pixels® Active Event Sensor (SPAES) is a novel category of ultra-low power and ultra-low latency 3D perception sensors for Extended Reality (XR)1 to blend the physical and digital worlds.
  • Extended Reality device manufacturers require low power consumption and low latency 3D perception technology to seamlessly blend the physical and digital worlds and unlock the true potential of immersive experiences.
  • “Our goal at VoxelSensors is to seamlessly integrate the physical and digital worlds to a point level where they become indistinguishable,” said Johannes Peeters, co-founder and CEO of VoxelSensors.
  • “With Switching Pixels® Active Event Sensing (SPAES) we challenge the status quo in 3D perception,” concludes VoxelSensors’ co-founder and CTO of VoxelSensors, PhD Ward van der Tempel.

Brussels Privacy Symposium 2022 Report

Retrieved on: 
Tuesday, March 21, 2023
People, FPF, Survivor, University of Colorado Boulder, International Observatory of Human Rights, Vrije Universiteit Brussel, University, European Data Protection Supervisor, BPH, Privacy, Future of Privacy Forum, Symposium (Plato), Hansot, CEO, EDPS, Associate, Future, LGPD, VUB, Leiden, Symposium, Global Privacy Enforcement Network, GDPR, Bias, Medical device, Management, Charles Chaynes

Brussels Privacy Symposium 2022 Report

Key Points: 
  • Brussels Privacy Symposium 2022 Report
    On November 15, 2022, the Future of Privacy Forum (FPF) and the Brussels Privacy Hub (BPH) of Vrije Universiteit Brussel (VUB) jointly hosted the sixth edition of the Brussels Privacy Symposium on the topic of “Vulnerable People, Marginalization, and Data Protection.” Participants explored the extent to which data protection and privacy law including the EU’s General Data Protection Regulation (GDPR) and other data protection laws like Brazil’s General Data Protection Law (LGPD) safeguard and empower vulnerable and marginalized people.
  • Participants also debated balancing the right to privacy with the need to process sensitive personal information to uncover and prevent bias and marginalization.
  • The event also marked the launch of VULNERA, the International Observatory on Vulnerable People in Data Protection, coordinated by the Brussels Privacy Hub and the Future of Privacy Forum.
  • This Report outlines some of the most noteworthy points raised by the speakers during the day-long Symposium.

Brussels Privacy Convening Focuses on Empowering Vulnerable and Marginalized People, Launches New Project

Retrieved on: 
Saturday, November 26, 2022
People, Future, European Digital Rights, Future of Privacy Forum, European Commission, European Network Against Racism, FPF, Digital data, Privacy, International Observatory of Human Rights, European Data Protection Supervisor, Racism, Policy, VUB, Research, Society, Global Privacy Enforcement Network, Woman, Bias, Information privacy, Disability, Digital rights, Person, GDPR, Industry, Organization, Color, Income, Medical device

Brussels Privacy Convening Focuses on Empowering Vulnerable and Marginalized People, Launches New Project

Key Points: 
  • Brussels Privacy Convening Focuses on Empowering Vulnerable and Marginalized People, Launches New Project
    The Future of Privacy Forum (FPF), a global non-profit focused on data protection and privacy, and the Brussels Privacy Hub of Vrije Universiteit Brussel (VUB) will jointly present the sixth edition of the Brussels Privacy Symposium on November 15, 2022.
  • The in-person event will convene in Brussels, bringing together policymakers, academic researchers, civil society, and industry representatives to discuss privacy research and scholarship.
  • In line with this years topic, Vulnerable People, Marginalization, and Data Protection, participants will explore the extent to which data protection and privacy law including GDPR and other modern data protection laws like Brazils LGPD safeguard and empower vulnerable and marginalized people.
  • The event marks the launch of VULNERA, the International Observatory on Vulnerable People in Data Protection, led by the Brussels Privacy Hub and supported by the Future of Privacy Forum.

DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)

Retrieved on: 
Wednesday, July 20, 2022
Radionuclide, Nuclear Physics Institute of the Czech Academy of Sciences, UJF, Deutsch, Board of directors, Camelidae, Radiopharmaceutical, Isotope, Federal Executive Boards, Research, ISIN, CGMP, Leukemia, Cancer, Micrometastasis, Neutralizing antibody, Nuclear medicine, Technology, FDA, Patient, VUB, Actinium-225, Drug Master File, SDAX, Colorectal cancer, Pharmaceutical industry, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.
  • This gives PRECIRIX priority access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225, which is used for the labeling of trial drugs in radionuclide therapy.
  • "Until now, clinical research and commercial use of Actinium-225 has been limited by the shortage of this radioisotope.
  • "We are particularly pleased to have an experienced radioisotope specialist like Eckert & Ziegler at our side to support our ambitious development plans."

Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix

Retrieved on: 
Wednesday, March 16, 2022
Research, Technology, Patient, Camelidae, VUB, VC, Do Meu Jeito, Vrije Universiteit Brussel, Capital, Cancer, CEO, Growth, Radionuclide, Radiopharmaceutical, Isotope, LinkedIn, Pharmaceutical industry

Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.

Key Points: 
  • Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
  • Paris, France, 16 March 2022 Jeito Capital (Jeito), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of 80 million in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology.
  • Jeito has co-led this investment with INKEF Capital and Forbion, two other leading European Life Sciences funds.
  • Dr Rafale Tordjman, Founder and CEO at Jeito Capital, said: We are pleased to have co-led this financing in Precirix alongside other high-quality European investors.

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

Retrieved on: 
Thursday, February 3, 2022
CEO, PMV, Health, Infection, RNA transfection, LTD, VUB, Engineering, LSP, Immunotherapy, Vaccination, Merck Group, Cancer, Partnership, Disease, NV, Antigen, Company, Science, Therapy, RNA, Solution, LNP, Pharmaceutical industry, Vaccine

The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany.

Key Points: 
  • The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany.
  • eTheRNA and Merck KGaA, Darmstadt, Germany both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases.
  • With this collaboration, eTheRNA and Merck KGaA, Darmstadt, Germany will assess the feasibility of using eTheRNA's mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease.
  • Steven Powell, eTheRNA CEO stated "We are extremely pleased to sign this partnership agreement with Merck KGaA, Darmstadt, Germany, a leading German science and technology company.

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

Retrieved on: 
Thursday, February 3, 2022
CEO, PMV, Health, Infection, RNA transfection, LTD, VUB, Engineering, LSP, Immunotherapy, Vaccination, Merck Group, Cancer, Partnership, Disease, NV, Antigen, Company, Science, Therapy, RNA, Solution, LNP, Pharmaceutical industry, Vaccine

The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany.

Key Points: 
  • The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany.
  • eTheRNA and Merck KGaA, Darmstadt, Germany both recognise the potential for using targeted mRNA therapeutics in an expanded range of diseases.
  • With this collaboration, eTheRNA and Merck KGaA, Darmstadt, Germany will assess the feasibility of using eTheRNA's mRNA and LNP technologies to develop therapeutic vaccination approaches in models of disease.
  • Steven Powell, eTheRNA CEO stated "We are extremely pleased to sign this partnership agreement with Merck KGaA, Darmstadt, Germany, a leading German science and technology company.